
Viking Therapeutics reports Q3 2026 results, $960M cash runway
Viking Therapeutics announced a Q3 loss, a $960 million cash cushion, and accelerated obesity trial activity for its VK2735 program.
Category

Viking Therapeutics announced a Q3 loss, a $960 million cash cushion, and accelerated obesity trial activity for its VK2735 program.

A fresh analysis shows pandemic‑era learning loss has left most districts far below 2019 benchmarks, exposing widening gaps and prompting new financial…

Credo debuts AI‑focused optical gear at OFC 2026 just as Microsoft announces a 19% revenue rise in its FY27 Q1 results.

Discover the key elements to consider when pricing AI projects in finance

Higher rates and inflation expectations are nudging the housing market toward slower sales, tighter inventory and renewed distress risk.

A fresh congressional proposal ties federal money to state funding, targeting full cost coverage for public‑college students and expanding aid to DREAMers.

Explore how top women in wealth management and Indian finance will shape the industry at two marquee events.

Ballot measures from coast to mountains are exposing how antiquated finance rules can’t cope with modern money wars.

Maximize the benefits of your free financial planning session with a comprehensive preparation guide

Moscow’s gold stockpile drops to its smallest size in seven years as fiscal pressures push the central bank to sell.